AzTrials
AzTrials

FibromyalgiaPhase 3NCT00883740

Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia

A Phase 3 study testing Pregabalin in people with Fibromyalgia and Sleep Disorders, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 50 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram) Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Fibromyalgia, Sleep Disorders
What is being tested?
Pregabalin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
119 participants
Where
50 sitesin 3 countries
Study dates
Jun 2009to Jun 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must meet diagnostic criteria for fibromyalgia;
  • Subjects must report difficulty in maintaining sleep at least 3 times per week and meet Research Diagnostic Criteria (RDC) for insomnia disorder, corroborated by subject diary, and meet PSG inclusion criteria at visit 3.

Who cannot join

  • History of active sleep disorder other than Research Diagnostic Criteria(RDC) insomnia criteria or any sleep or circadian rhythm disturbance;
  • Use of medications known to affect sleep wake function by Visit 2;
  • Involved in night or rotating shift work, or travel across >4 time zones 14 days prior to screening and during study; regular daytime napping
  • PSG finding of apnea/hypopnea or periodic limb movement with arousal index >10/hr on either night of PSG.

Trial locations and contacts

50 sites in 3 countries.

50 sites in 3 countries

United States30 sites
  • Pfizer Investigational Site

    Atlanta, Georgia, 30342

  • Pfizer Investigational Site

    Baton Rouge, Louisiana, 70809

  • Pfizer Investigational Site

    Beachwood, Ohio, 44122

  • Pfizer Investigational Site

    Chicago, Illinois, 60634

  • Pfizer Investigational Site

    Cleveland, Ohio, 44122

  • Pfizer Investigational Site

    Colorado Springs, Colorado, 80909

  • Pfizer Investigational Site

    Columbia, South Carolina, 29201

  • Pfizer Investigational Site

    Crestview Hills, Kentucky, 41017

  • Pfizer Investigational Site

    Dallas, Texas, 75230

  • Pfizer Investigational Site

    Dallas, Texas, 75248

  • Pfizer Investigational Site

    DeLand, Florida, 32720

  • Pfizer Investigational Site

    Duncansville, Pennsylvania, 16635

  • Pfizer Investigational Site

    Hallandale, Florida, 33009

  • Pfizer Investigational Site

    Hattiesburg, Mississippi, 39401

  • Pfizer Investigational Site

    Hattiesburg, Mississippi, 39402

  • Pfizer Investigational Site

    Houston, Texas, 77063

  • Pfizer Investigational Site

    Louisville, Kentucky, 40217

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73103

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Orange City, Florida, 32763

  • Pfizer Investigational Site

    Overland Park, Kansas, 66212

  • Pfizer Investigational Site

    Pembroke Pines, Florida, 33026

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19114

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19139

  • Pfizer Investigational Site

    Phoenix, Arizona, 85013

  • Pfizer Investigational Site

    Phoenix, Arizona, 85020

  • Pfizer Investigational Site

    Raleigh, North Carolina, 27612

  • Pfizer Investigational Site

    San Diego, California, 92102

  • Pfizer Investigational Site

    South Miami, Florida, 33143

  • Pfizer Investigational Site

    Tucson, Arizona, 85741

Other trials in United States

Canada10 sites
  • Pfizer Investigational Site

    Calgary, Alberta, T2X 3V4

  • Pfizer Investigational Site

    Edmonton, Alberta, T5R 5W5

  • Pfizer Investigational Site

    Kelowna, British Columbia, V1Y 3G8

  • Pfizer Investigational Site

    Kelowna, British Columbia, V1Y 4R9

  • Pfizer Investigational Site

    Mississauga, Ontario, L5B 4M4

  • Pfizer Investigational Site

    Point Edward, Ontario, N7V 1X4

  • Pfizer Investigational Site

    Thornhill, Ontario, L4J 6X2

  • Pfizer Investigational Site

    Toronto, Ontario, M3H 3V6

  • Pfizer Investigational Site

    Toronto, Ontario, M4P 1P2

  • Pfizer Investigational Site

    Toronto, Ontario, M6J 3S3

Other trials in Canada

Germany10 sites
  • Pfizer Investigational Site

    Berlin, 10117

  • Pfizer Investigational Site

    Berlin, 10969

  • Pfizer Investigational Site

    Berlin, 12683

  • Pfizer Investigational Site

    Berlin, 13125

  • Pfizer Investigational Site

    Chemnitz, 09111

  • Pfizer Investigational Site

    Göppingen, 73033

  • Pfizer Investigational Site

    Göppingen, 73035

  • Pfizer Investigational Site

    München, 80336

  • Pfizer Investigational Site

    München, 81675

  • Pfizer Investigational Site

    Schwerin, 19053

Other trials in Germany

About this study

Official title: Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study

The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)

Being tested
Pregabalin, Placebo
Keywords
Fibromyalgia sleep maintenance disturbance pregabalin
Medical subject headings
Fibromyalgia, Sleep Wake Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PregabalinDrug

    Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day

  • PlaceboDrug

    Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks

Study groups in NCT00883740
Study groupRoleWhat they receive
LyricaExperimentalflexible dosing Lyrica 300-450mg/day
Receives: Drug: Pregabalin
PlaceboPlacebo comparatorPlacebo
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wake After Sleep Onset (WASO) at Weeks 5 and 11

    WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography [PSG]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording [i.e. awake epoch immediately prior to the end of the recording]) on 2 consecutive nights divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)

Secondary outcomes (17)
  1. Wake Time During Sleep (WTDS)

    WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  2. Wake Time After Sleep (WTAS)

    WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  3. Total Sleep Time (TST)

    TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  4. Sleep Efficiency (SE)

    SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  5. Number of Awakenings After Sleep Onset (NAASO 1)

    NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  6. Number of Awakenings After Sleep Onset (NAASO 2)

    NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  7. Latency to Persistent Sleep (LPS)

    LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  8. WASO by Hour of the Night

    WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total).

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  9. WASO by Each Quarter of the Night

    WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments).

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  10. Slow Wave Sleep (SWS)

    SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.

    Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET

  11. Change From Baseline in MOS-SS Sleep Disturbance at Weeks 5 and 11

    MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline.

    Measured: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET

  12. Change From Baseline in MOS-SS Sleep Problems Index II Weeks 5 and 11

    MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline.

    Measured: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET

  13. Sleep Quality

    Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores.

    Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET

  14. Latency of Sleep Onset (LSO)

    LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ.

    Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET

  15. Daily Pain Score

    Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores.

    Measured: Daily up to Day 73 or ET

  16. Subjective Wake After Sleep Onset (sWASO)

    sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values.

    Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET

  17. Subjective Total Sleep Time (sTST)

    sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values.

    Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2009 (estimated)
  2. Study startJun 2009
  3. Primary completionJun 2010
  4. Study completionJun 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
119 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00883740
Sponsor's protocol ID
A0081165
Status last verified
Jul 2011
First submitted
17 Apr 2009
Last updated
25 Jan 2021
Data monitoring committee
Yes

Publications

  • Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken). 2012 Apr;64(4):597-606. doi: 10.1002/acr.21595.

    PubMed 22232085

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Pregabalin in people with Fibromyalgia and Sleep Disorders, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 50 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 50 sites in United States, Canada, Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Aug 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wake After Sleep Onset (WASO) at Weeks 5 and 11 (time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00883740, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in